The present invention provides a preparation method for PCV2 capsid protein and a pharmaceutical composition containing said capsid protein. The method of the present invention uses a novel arabinose-induced expression vector and thereby improves the synthesis efficiency of said PCV2 capsid protein. On the other hand, the present pharmaceutical composition combines said capsid protein and other favorable components at a proper ratio so that achieves excellent immune-inducing effects.

Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.

The present invention provides a preparation method for PCV2 capsid protein and a pharmaceutical composition containing said capsid protein. The method of the present invention uses a novel arabinose-induced expression vector and thereby improves the synthesis efficiency of said PCV2 capsid protein. On the other hand, the present pharmaceutical composition combines said capsid protein and other favorable components at a proper ratio so that achieves excellent immune-inducing effects.

The present invention relates to a novel recombinant porcine circovirus type 2 protein and use thereof and, more specifically, to: a novel recombinant porcine circovirus type 2 protein; and a vaccine composition, an immunogenic composition, and a feed composition, comprising same. It was confirmed that the novel recombinant porcine circovirus type 2 protein according to the present invention showed excellent antibody titers against both PCV2b and type 2d. This means that when the recombinant porcine circovirus type 2 protein of the present invention is used as a vaccine, porcine circovirus-related diseases can be effectively prevented by cross-protecting both PCV2b and PCV2d genotypes, and thus the porcine circovirus type 2 protein of the present invention can be used in various ways in the field of pig farming.

Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.

The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.

Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.